Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening

Overview

Journal J Natl Compr Canc Netw

Specialty Oncology

Date 2016 Nov 2

PMID 27799515

Citations 14

Authors

Christina D Williams

William M Grady

Leah L Zullig

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) remains a common cancer and significant public health burden. CRC-related mortality is declining, partly due to the early detection of CRC through robust screening. NCCN has established the NCCN Guidelines for CRC Screening to help healthcare providers make appropriate screening recommendations according to the patient's risk of developing CRC. This review describes the evolution of CRC screening guidelines for average-risk individuals, discusses the role of NCCN Guidelines for CRC Screening in cancer prevention, and comments on the current and emerging use of biomarkers for CRC screening.

Citing Articles

Effectiveness of colonoscopy, immune fecal occult blood testing, and risk-graded screening strategies in colorectal cancer screening.

Xu M, Yang J, Meng T World J Gastrointest Surg. 2024; 16(7):2270-2280.

PMID: 39087098 PMC: 11287692. DOI: 10.4240/wjgs.v16.i7.2270.

Prediction and analysis of albumin-bilirubin score combined with liver function index and carcinoembryonic antigen on liver metastasis of colorectal cancer.

Wang Z, Pan S, Zhang J, Zhou J World J Gastrointest Surg. 2024; 16(6):1670-1680.

PMID: 38983332 PMC: 11230030. DOI: 10.4240/wjgs.v16.i6.1670.

Association of Disparities in Family History and Family Cancer History in the Electronic Health Record With Sex, Race, Hispanic or Latino Ethnicity, and Language Preference in 2 Large US Health Care Systems.

Chavez-Yenter D, Goodman M, Chen Y, Chu X, Bradshaw R, Lorenz Chambers R JAMA Netw Open. 2022; 5(10):e2234574.

PMID: 36194411 PMC: 9533178. DOI: 10.1001/jamanetworkopen.2022.34574.

A Retrospective Study from a Single Center to Identify Hematological Factors that Distinguish Between Patients with Colorectal Carcinoma and Colorectal Adenoma.

Huang J, Xu P, Chen Y Med Sci Monit. 2022; 28:e936745.

PMID: 35945827 PMC: 9377193. DOI: 10.12659/MSM.936745.

Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases.

Loosen S, Roderburg C, Alizai P, Roeth A, Schmitz S, Vucur M Diagnostics (Basel). 2021; 11(11).

PMID: 34829346 PMC: 8622404. DOI: 10.3390/diagnostics11111999.

References

Imperiale T, Ransohoff D, Itzkowitz S, Levin T, Lavin P, Lidgard G . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 370(14):1287-97. DOI: 10.1056/NEJMoa1311194. View

Lieberman D, Rex D, Winawer S, Giardiello F, Johnson D, Levin T . Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143(3):844-857. DOI: 10.1053/j.gastro.2012.06.001. View

Leung W, To K, Man E, Chan M, Hui A, Ng S . Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007; 102(5):1070-6. DOI: 10.1111/j.1572-0241.2007.01108.x. View

Hellebrekers D, Lentjes M, van den Bosch S, Melotte V, Wouters K, Daenen K . GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009; 15(12):3990-7. DOI: 10.1158/1078-0432.CCR-09-0055. View

Stanley S, King J, Thomas C, Richardson L . Factors associated with never being screened for colorectal cancer. J Community Health. 2012; 38(1):31-9. DOI: 10.1007/s10900-012-9600-x. View

Glockner S, Dhir M, Yi J, McGarvey K, Van Neste L, Louwagie J . Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009; 69(11):4691-9. PMC: 3062162. DOI: 10.1158/0008-5472.CAN-08-0142. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Klabunde C, Zheng Y, Quinn V, Beaber E, Rutter C, Halm E . Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med. 2016; 51(3):e67-75. PMC: 4992638. DOI: 10.1016/j.amepre.2016.04.018. View

Lidgard G, Domanico M, Bruinsma J, Light J, Gagrat Z, Oldham-Haltom R . Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013; 11(10):1313-8. DOI: 10.1016/j.cgh.2013.04.023. View

10.

Bibbins-Domingo K, C Grossman D, Curry S, Davidson K, Epling Jr J, Garcia F . Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 315(23):2564-2575. DOI: 10.1001/jama.2016.5989. View

11.

Lofton-Day C, Model F, deVos T, Tetzner R, Distler J, Schuster M . DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2007; 54(2):414-23. DOI: 10.1373/clinchem.2007.095992. View

12.

van Roessel P, Rouse R, Wren S . Care within a veterans hospital: earlier detection of colon cancer. Surg Endosc. 2007; 21(8):1434-40. DOI: 10.1007/s00464-006-9184-6. View

13.

Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N . Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2014; 30(5):830-3. DOI: 10.1111/jgh.12855. View

14.

Provenzale D, Jasperson K, Ahnen D, Aslanian H, Bray T, Cannon J . Colorectal Cancer Screening, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(8):959-68. DOI: 10.6004/jnccn.2015.0116. View

15.

Whitlock E, Lin J, Liles E, Beil T, Fu R . Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9):638-58. DOI: 10.7326/0003-4819-149-9-200811040-00245. View

16.

Leung W, To K, Man E, Chan M, Bai A, Hui A . Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 2005; 100(10):2274-9. DOI: 10.1111/j.1572-0241.2005.50412.x. View

17.

Byers T, Levin B, Rothenberger D, Dodd G, Smith R . American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin. 1997; 47(3):154-60. DOI: 10.3322/canjclin.47.3.154. View

18.

Lin J, Piper M, Perdue L, Rutter C, Webber E, OConnor E . Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 315(23):2576-94. DOI: 10.1001/jama.2016.3332. View

19.

Levin B, Lieberman D, McFarland B, Andrews K, Brooks D, Bond J . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134(5):1570-95. DOI: 10.1053/j.gastro.2008.02.002. View

20.

Melotte V, Lentjes M, van den Bosch S, Hellebrekers D, de Hoon J, Wouters K . N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009; 101(13):916-27. DOI: 10.1093/jnci/djp131. View